|
1
|
Napier KJ, Scheerer M and Misra S:
Esophageal cancer: A review of epidemiology, pathogenesis, staging
workup and treatment modalities. World J Gastrointest Oncol.
6:112–120. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen WS, Zheng R, Zhang S, Zhao P, Zeng H,
Zou X and He J: Annual report on status of cancer in China, 2010.
Chin J Cancer Res. 26:48–58. 2014.PubMed/NCBI
|
|
3
|
Arnold M, Soerjomataram I, Ferlay J and
Forman D: Global incidence of oesophageal cancer by histological
subtype in 2012. Gut. 64:381–387. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chen W, He Y, Zheng R, Zhang S, Zeng H,
Zou X and He J: Esophageal cancer incidence and mortality in China,
2009. J Thorac Dis. 5:19–26. 2013.PubMed/NCBI
|
|
6
|
Merkow RP, Bilimoria KY, Keswani RN, Chung
J, Sherman KL, Knab LM, Posner MC and Bentrem DJ: Treatment trends,
risk of lymph node metastasis, and outcomes for localized
esophageal cancer. J Natl Cancer Inst. 106:pii: dju133. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Andrew C, Fergus N and Timothy U:
Strategies to improve outcomes in esophageal adenocarcinoma. Expert
Rev Anticancer Ther. 14:677–687. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cheng GF: Circulating miRNAs: Roles in
cancer diagnosis, prognosis and therapy. Adv Drug Deliv Rev.
81:75–93. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Calin GA, Sevignani C, Dumitru CD, Hyslop
T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M
and Croce CM: Human microRNA genes are frequently located at
fragile sites and genomic regions involved in cancers. P Natl Acad
Sci USA. 101:2999–3004. 2004. View Article : Google Scholar
|
|
10
|
Chen Y, Song Y, Wang Z, Yue Z, Xu H, Xing
C and Liu Z: Altered expression of miR-148a and miR-152 in
gastrointestinal cancers and its clinical significance. J
Gastrointest Surg. 14:1170–1179. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xu Q, Jiang Y, Yin Y, Li Q, He J, Jing Y,
Qi YT, Xu Q, Li W, Lu B, et al: A regulatory circuit of
miR-148a/152 and DNMT1 in modulating cell transformation and tumor
angiogenesis through IGF-IR and IRS1. J Mol Cell Biol. 5:3–13.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhou X, Zhao F, Wang ZN, Song YX, Chang H,
Chiang Y and Xu HM: Altered expression of miR-152 and miR-148a in
ovarian cancer is related to cell proliferation. Oncol Rep.
27:447–454. 2012.PubMed/NCBI
|
|
13
|
Zhang H, Li Y, Huang Q, Ren X, Hu H, Sheng
H and Lai M: MiR-148a promotes apoptosis by targeting Bcl-2 in
colorectal cancer. Cell Death Differ. 18:1702–1710. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Murata T, Takayama K, Katayama S, Urano T,
Horie-Inoue K, Ikeda K, Takahashi S, Kawazu C, Hasegawa A, Ouchi Y,
et al: miR-148a is an androgen-responsive microRNA that promotes
LNCaP prostate cell growth by repressing its target CAND1
expression. Prostate Cancer Prostatic Dis. 13:356–361. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hummel R, Hussey DJ, Michael MZ, Haier J,
Bruewer M, Senninger N and Watson DI: MiRNAs and their association
with locoregional staging and survival following surgery for
esophageal carcinoma. Ann Surg Oncol. 18:253–260. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hummel R, Watson DI, Smith C, Kist J,
Michael MZ, Haier J and Hussey DJ: Mir-148a improves response to
chemotherapy in sensitive and resistant oesophageal adenocarcinoma
and squamous cell carcinoma cells. J Gastrointest Surg. 15:429–438.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tan Z, Randall G, Fan J, Camoretti-Mercado
B, Brockman-Schneider R, Pan L, Solway J, Gern JE, Lemanske RF,
Nicolae D and Ober C: Allele-specific targeting of microRNAs to
HLA-G and risk of asthma. Am J Hum Genet. 81:829–834. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Manaster I, Goldman-Wohl D, Greenfield C,
Nachmani D, Tsukerman P, Hamani Y, Yagel S and Mandelboim O:
MiRNA-mediated control of HLA-G expression and function. PLoS One.
7:e333952012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Carosella ED, Moreau P, LeMaoult J and
Rouas-Freiss N: HLA-G: From biology to clinical benefits. Trends
Immunol. 29:125–132. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chang CC, Campoli M and Ferrone S: HLA
class I antigen expression in malignant cells: Why does it not
always correlate with CTL-mediated lysis? Curr Opin Immunol.
16:644–650. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yie SM, Yang H, Ye SR, Li K, Dong DD and
Lin XM: Expression of HLA-G is associated with prognosis in
esophageal squamous cell carcinoma. Am J Clin Pathol.
128:1002–1009. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cao M, Yie SM, Liu J, Ye S, Xia D and Gao
E: Plasma soluble HLA-G is a potential biomarker for diagnosis of
colorectal, gastric, esophageal and lung cancer. Tissue Antigens.
78:120–128. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rice TW: Esophageal cancer staging. Korean
J Thorac Cardiovasc Surg. 48:157–163. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Napier KJ, Scheerer M and Misra S:
Esophageal cancer: A Review of epidemiology, pathogenesis, staging
workup and treatment modalities. World J Gastrointest Oncol.
6:112–120. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Berindan-Neagoe I, Monroig P, Pasculli B
and Calin GA: MicroRNAome genome: A treasure for cancer diagnosis
and therapy. CA Cancer J Clin. 64:311–336. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Guo SL, Peng Z, Yang X, Fan KJ, Ye H, Li
ZH, Wang Y, Xu XL, Li J, Wang YL, et al: miR-148a promoted cell
proliferation by targeting p27 in gastric cancer cells. Int J Biol
Sci. 7:567–574. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zheng B, Liang L, Wang C, Huang S, Cao X,
Zha R, Liu L, Jia D, Tian Q, Wu J, et al: Microrna-148a suppresses
tumor cell invasion and metastasis by downregulating rock1 in
gastric cancer. Clin Cancer Res. 17:7574–7583. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yuan K, Lian Z, Sun B, Clayton MM, Ng Io
and Feitelson MA: Role of miR-148a in hepatitis B associated
hepatocellular carcinoma. PLoS One. 7:e353312012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Geraghty DE, Koller BH and Orr HT: A human
major histocompatibility complex class I gene that encodes a
protein with a shortened cytoplasmic segment. Proc Natl Acad Sci
USA. 84:9145–9149. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Paul P, Cabestre Adrian FA, Ibrahim EC,
Lefebvre S, Khalil-Daher I, Vazeux G, Quiles RM, Bermond F, Dausset
J and Carosella ED: Identification of HLA-G7 as a new splice
variant of the HLA-G mRNA and expression of soluble HLA-G5, -G6 and
-G7 transcripts in human transfected cells. Hum Immunol.
61:1138–1149. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Rizzo R, Vercammen M, van de Velde H, Horn
PA and Rebmann V: The importance of HLA-G expression in embryos,
trophoblast cells and embryonic stem cells. Cell Mol Life Sci.
68:341–352. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Rouas-Freiss N, Moreau P, Ferrone S and
Carosella D: HLA-G proteins in cancer: Do they provide tumor cells
with an escape mechanism? Cancer Res. 65:10139–10144. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Menendez L, Walker LD, Matyunina LV,
Totten KA, Benigno BB and McDonald JF: Epigenetic changes within
the promoter region of the HLA-G gene in ovarian tumors. Mol
Cancer. 7:1–11. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Moreau P, Mouillot G, Rousseau P, Marcou
C, Dausset J and Carosella ED: HLA-G gene repression is reversed by
demethylation. Proc Natl Acad Sci USA. 100:1191–1196. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Mouillot G, Marcou C, Rousseau P,
Rouas-Freiss N, Carosella ED and Moreau P: HLA-G gene activation in
tumor cells involves cis-acting epigenetic changes. Int J Cancer.
113:928–936. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Braconi C, Huang N and Patel T:
MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor
suppressor gene expression by interleukin-6 in human malignant
cholangiocytes. Hepatology. 51:881–890. 2010.PubMed/NCBI
|
|
38
|
Duursma AM, Kedde M, Schrier M, le Dage C
and Agami R: miR-148 targets human DNMT3b protein coding region.
RNA. 14:872–877. 2008. View Article : Google Scholar : PubMed/NCBI
|
